High-Density Lipoproteins Protect Isolated Rat Hearts From Ischemia-Reperfusion Injury by Reducing Cardiac Tumor Necrosis Factor-α Content and Enhancing Prostaglandin Release
- 21 February 2003
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 92 (3) , 330-337
- https://doi.org/10.1161/01.res.0000054201.60308.1a
Abstract
The incidence and severity of primary cardiac events are inversely related to the plasma concentration of high-density lipoproteins (HDLs). We investigated whether HDLs may exert a direct cardioprotection in buffer-perfused isolated rat hearts, which underwent a 20-minute low-flow ischemia followed by a 30-minute reperfusion. The administration of HDLs at physiological concentrations (0.5 and 1.0 mg/mL) during the 10 minutes immediately before ischemia rapidly and remarkably improved postischemic functional recovery and decreased creatine kinase release in the coronary effluent. Reconstituted HDLs containing apolipoprotein A-I (apoA-I) and phosphatidylcholine, but not lipid-free apoA-I or phosphatidylcholine liposomes, were also effective in protecting the heart from ischemia-reperfusion injury. HDLs at reperfusion were less effective than when given before ischemia. HDLs caused a dose-dependent reduction of ischemia-induced cardiac tumor necrosis factor-α (TNF-α) expression and content, which correlated with the improved functional recovery. A parallel increase of TNF-α release in the coronary effluent was observed, due to a direct binding of cardiac TNF-α to HDLs. Taken together, these findings argue for a cause-effect relationship between the HDL-mediated removal of TNF-α from the ischemic myocardium and the HDL-induced cardioprotection. Indeed, etanercept, a recombinant TNF-α–blocking protein, caused a dose-dependent improvement of postischemic functional recovery. HDLs also enhanced ischemia-induced prostaglandin release, which may contribute to the cardioprotective effect. A low plasma HDL level may expose the heart to excessive ischemia-reperfusion damage, and HDL-targeted therapies may be helpful to induce immediate or delayed myocardial protection from ischemia-reperfusion injury.Keywords
This publication has 26 references indexed in Scilit:
- Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioningCardiovascular Research, 2002
- Tumor Necrosis Factor-α Blockade: A Novel Therapy for Rheumatic DiseaseClinical Immunology, 2002
- The inflammatory response in myocardial infarctionCardiovascular Research, 2002
- Regulation of TNFα and interleukin-10 production by prostaglandins I2 and E2: studies with prostaglandin receptor-deficient mice and prostaglandin E-receptor subtype-selective synthetic agonistsBiochemical Pharmacology, 2001
- Gemfibrozil for the Secondary Prevention of Coronary Heart Disease in Men with Low Levels of High-Density Lipoprotein CholesterolNew England Journal of Medicine, 1999
- Influence of baseline lipids on effectiveness of pravastatin in the CARE trialJournal of the American College of Cardiology, 1999
- Tumor necrosis factor-alpha is released from the isolated heart undergoing ischemia and reperfusionJournal of the American College of Cardiology, 1996
- Angiographically silent atherosclerosis detected by intravascular ultrasound in patients with familial hypercholesterolemia and familial combined hyperlipidemia: Correlation with high density lipoproteinsJournal of the American College of Cardiology, 1996
- High-Density Lipoprotein — The Clinical Implications of Recent StudiesNew England Journal of Medicine, 1989
- Prostacyclin protects ischemic reperfused myocardium in the dog by inhibition of neutrophil activationAmerican Heart Journal, 1987